MHRA Alert – Bromocriptine: Blood Pressure Monitoring Essential

Blood Pressure Monitoring Required for Bromocriptine Use

The MHRA has issued a safety update following a Yellow Card report concerning bromocriptine prescribed for prevention or inhibition of post-partum physiological lactation. A safety review has concluded that blood pressure monitoring is essential when prescribing this medication.

Key Points

• Bromocriptine carries a risk of blood pressure elevation in post-partum patients
• Baseline blood pressure assessment and ongoing monitoring are recommended before and during treatment
• Healthcare providers should be alert to signs of hypertension or hypertensive crisis
• Patient counselling should include awareness of potential cardiovascular effects

Affected Medication

• Bromocriptine – all formulations used for post-partum lactation prevention or inhibition

Recommended Actions

• Check blood pressure before initiating bromocriptine therapy
• Implement regular blood pressure monitoring during treatment
• Document baseline readings and any changes in patient records
• Advise patients to report headache, visual disturbances, chest pain, or other signs of hypertension
• Review the full MHRA guidance for additional clinical context

Read the full MHRA safety update